Loading...
•
Sep 30, 2021
Maravai Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021 and updated 2021 financial guidance.
Key Takeaways
Maravai LifeSciences reported a strong third quarter with revenue increasing by 133% to $204.8 million and net income of $132.8 million, representing a 240% growth over the prior year. The company also increased its 2021 revenue guidance to a range of $770.0 million to $780.0 million and established initial 2022 revenue guidance range of $840.0 million to $880.0 million.
Revenue increased 133% to $204.8 million for the third quarter.
Net income of $132.8 million for the third quarter, representing growth of 240% over the prior year.
2021 revenue guidance increased to a range of $770.0 million to $780.0 million.
Established initial 2022 revenue guidance range of $840.0 million to $880.0 million.
Revenue by Segment
Forward Guidance
Maravai provided preliminary revenue guidance for 2022, projecting total revenue to be in the range of $840.0 million to $880.0 million, reflecting overall growth at the midpoints of 11% and 14% before and after adjusting for the divestiture of our Protein Detection Business, respectively.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...